RT Conference Proceedings
T1 Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel plus Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
A1 Morgensztern, D.
A1 Govindan, R.
A1 Cobo, M.
A1 Ponce Aix, S.
A1 Postmus, P. E.
A1 Lewanski, C.
A1 Bennouna, J.
A1 Fischer, J.
A1 Juan-Vidal, O.
A1 Stewart, D.
A1 Ardizzoni, A.
A1 Bhore, R.
A1 Wolfsteiner, M.
A1 Reck, M.
A1 Talbot, D.
A1 Ong, T. J.
K1 nab-paclitaxel
K1 survival
K1 durvalumab
PB Elsevier science inc
SN 1556-0864
YR 2018
FD 2018-10-01
LK https://hdl.handle.net/10668/27914
UL https://hdl.handle.net/10668/27914
LA en
DS RISalud
RD Apr 17, 2025